The fact that the "room temperature" option needs
Post# of 36537
(Total Views: 342)
Posted On: 06/18/2020 10:44:17 AM
The fact that the "room temperature" option needs limited funding to solve is heartening, but it's still a roadblock to current sales. So the Q I had written down for the next CC was what % of VA hospitals and/or potential sales are contingent on this room temperature issue vs. the locations/sales they can go after with the current refrigerated product...
Additional research and development is expected for Excellagen to enhance the product to allow the product to be used in VA Hospitals that require treatments as “room temperature.”
The product Excellagen® is complete with active sales. Without additional funding to create a viable “room temperature” product for VA Hospitals, its full potential would not realized. Excellagen has received the FDA 510K approval with 17 indications, but any additional indications and treatments will require additional funding to fully exploit Excellegen’s potential including combining Excellagen with Exassome to create the viable product Excellasome®.
No additional resources are currently needed for Excellagen® to complete the project as it has FDA 510K approval with active sales. Limited funding is required to develop the project further to create a viable “room temperature” product noted above. Excellagen® became a viable commercial product after acquisition with active sales.
Additional research and development is expected for Excellagen to enhance the product to allow the product to be used in VA Hospitals that require treatments as “room temperature.”
The product Excellagen® is complete with active sales. Without additional funding to create a viable “room temperature” product for VA Hospitals, its full potential would not realized. Excellagen has received the FDA 510K approval with 17 indications, but any additional indications and treatments will require additional funding to fully exploit Excellegen’s potential including combining Excellagen with Exassome to create the viable product Excellasome®.
No additional resources are currently needed for Excellagen® to complete the project as it has FDA 510K approval with active sales. Limited funding is required to develop the project further to create a viable “room temperature” product noted above. Excellagen® became a viable commercial product after acquisition with active sales.
(2)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼